Leerink Partners Thinks Aligos Therapeutics’ Stock is Going to Recover

In a report issued on October 11, Jim Kelly from Leerink Partners maintained a Buy rating on Aligos Therapeutics (ALGSResearch Report). The company’s shares closed last Wednesday at $14.95, close to its 52-week low of $12.82.

According to TipRanks.com, Kelly is a 1-star analyst with an average return of -0.7% and a 27.3% success rate. Kelly covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Atea Pharmaceuticals, and scPharmaceuticals.

Currently, the analyst consensus on Aligos Therapeutics is a Moderate Buy with an average price target of $47.00.

See the top stocks recommended by analysts >>

Based on Aligos Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.55 million and GAAP net loss of $29.82 million. In comparison, last year the company had a GAAP net loss of $20.8 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).